Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03619837 · ClinicalTrials.gov registry record · Phase 4
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
A Phase 4 study of Hepatitis C and Transplantation Disease Transmission, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 122
- Enrollment target
- 6
- Study locations
NCT03619837 is a Phase 4 study of Hepatitis C and Transplantation Disease Transmission that has completed, run by University of California, San Francisco. The registered enrollment target is 122 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT03619837, a Phase 4 study of Hepatitis C and Transplantation Disease Transmission, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 122 participants
- Enrollment target
- 6
- Study locations
Study Summary
In this study, subjects that do not have Hepatitis C virus (HCV) will be transplanted with livers or kidneys from donors who do have HCV. Medications that are used to treat HCV will be given to the study subjects shortly after transplant to protect them from developing the problems HCV can cause to the liver.
Conditions Studied
Interventions
- DRUG Sofosbuvir/Velpatasvir
- DRUG Sofosbuvir/Velpatasvir/Voxilaprevir
Study Locations (6)
Texas
- Baylor University Medical Center - Dallas - Dallas
- Houston Methodist Hospital - Houston
California
- University of California, San Francisco - San Francisco
Colorado
- University of Colorado Denver - Aurora
Georgia
- Piedmont Research Institute - Atlanta
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2018-07-15 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03619837
The ClinicalTrials.gov registry entry for NCT03619837 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Sofosbuvir/Velpatasvir is the first listed.
NCT03619837 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03619837 about?
NCT03619837 is a clinical study titled "Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant". In this study, subjects that do not have Hepatitis C virus (HCV) will be transplanted with livers or kidneys from donors who do have HCV. Medications that are used to treat HCV will be given to the study subjects shortly after transplant to protect them from developing the problems HCV can cause to ...
What is the current status of trial NCT03619837?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2018-07-15. Estimated completion is 2020-08-13.
What conditions does trial NCT03619837 study?
This clinical trial studies the following conditions: Hepatitis C, Transplantation Disease Transmission.
What interventions are being tested in trial NCT03619837?
The interventions under investigation include: Sofosbuvir/Velpatasvir (DRUG), Sofosbuvir/Velpatasvir/Voxilaprevir (DRUG).
Who is sponsoring clinical trial NCT03619837?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03619837 being conducted?
This trial has 6 study locations across California, Colorado, Georgia, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
-
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
COMPLETED · Phase 4
-
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
COMPLETED · Phase 4
-
The Kentucky Viral Hepatitis Treatment Study
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.